Respiratory Syncytial Virus
Conditions
Keywords
Viral Diseases, Messenger RNA, Moderna, mRNA-1345, Respiratory syncytial virus, Safety, Vaccines, Immunocompromised, Organ transplant
Brief summary
The study is divided into 2 parts (Part A and Part B). Part A of the study will evaluate the safety and immune response to mRNA-1345 in high-risk adults aged ≥18 to \<60 years. Part B of the study will evaluate the safety and immune response to mRNA-1345 in adults who received solid organ transplant (SOT).
Interventions
BIOLOGICALmRNA-1345
Sterile liquid for injection
Sponsors
ModernaTX, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Part A: double-blind Part B: open-label (no masking)
Intervention model description
Part A participants will be randomized into 2 treatment dose groups at a 1:1 ratio. Part B is non-randomized.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: Part A: * Adults ≥18 to \<60 years of age at the time of consent who are primarily responsible for self-care and activities of daily living. * Documented confirmation by a physician of the diagnosis of at least one of the following conditions: 1. Coronary artery disease and/or congestive heart failure. 2. Chronic lung disease (for example, including but not limited to chronic obstructive pulmonary disease or persistent asthma). 3. Stable type 1 or type 2 diabetes mellitus controlled with at least 1 medication started 90 days or more prior to Day 1. Part B: * Adults ≥18 years of age at the time of consent who are primarily responsible for self-care and activities of daily living. * Recipient of an SOT (kidney, liver, or lung transplant) ≥180 days prior to day of consent and receiving chronic immunosuppressive therapy for the prevention of allograft rejection. Parts A and B: \- Able to comply with study requirements. Key
Exclusion criteria
Part A: * Participation in an another clinical research trial where the participant has received an investigational product 180 days prior to Day 1. Participation in an RSV trial at any time prior to Day 1 is exclusionary. * History of a diagnosis or condition, that, in the judgment of the Investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures. * Reported history of anaphylaxis or severe hypersensitivity reaction after receipt of the mRNA-1345 injection or any components of the mRNA-1345 injection. * Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 180 days prior to Day 1. * History of myocarditis, pericarditis, or myopericarditis. Part B: * Previous treatment with alemtuzumab or rituximab within 2 years prior to Day 1. * Previous treatment with plasmapheresis within 30 days prior to Day 1. * A history of complications of immunosuppression. * A history of biopsy proven or clinically diagnosed rejection within 90 days prior to Day 1 or suspected active chronic rejection according to the Investigator's judgment. Note: Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) | Day 1 through Day 7 (7 days post injection) for Part A and Day 1 through Day 64 (7 days post second injection) for Part B |
| Number of Participants with Unsolicited Adverse Events (AEs) | Day 1 through Day 28 (28 days post injection) for Part A and Day 1 through Day 84 (28 days post second injection) for Part B |
| Number of Participants With Medically Attended AEs (MAAEs) | Day 1 through Month 6 (for Part A) and Day 1 through Month 9 (for Part B) |
| Number of Participants With Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and AEs Leading to Discontinuation | Day 1 through End of Study (Day 730) |
| Part A: Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) and Respiratory Syncytial Virus Subtype B (RSV-B) Neutralizing Antibodies (Abs) at Day 29 | Day 29 |
| Part B: GMT of Serum RSV-A and RSV-B Neutralizing Abs at Day 85 | Day 85 |
Secondary
| Measure | Time frame |
|---|---|
| Part A: GMT of Postinjection/Baseline Titers to RSV-A and RSV-B Neutralizing Abs | Baseline up to Day 730 |
| Part A: GMFR of Postinjection/Baseline Titers to RSV-A and RSV-B Neutralizing Abs | Baseline up to Day 730 |
| Part A: SRR of Serum RSV-A and RSV-B Neutralizing Abs | Up to End of Study (Day 730) |
| Part A: Number of Participants with ≥2-Fold Increase in RSV-A and RSV-B Neutralizing Abs Titers | Up to End of Study (Day 730) |
| Part B: GMT of Serum RSV-A and RSV-B Neutralizing Abs at Day 29 | Day 29 |
| Part B: SRR of Serum RSV-A and RSV-B Neutralizing Abs on Day 29 | Day 29 |
| Part B: SRR of Serum RSV-A and RSV-B Neutralizing Abs on Day 85 | Day 85 |
| Part A: Seroresponse Rate (SRR) of RSV-A and RSV-B Neutralizing Abs on Day 29 | Day 29 |
| Part B: GMFR of Serum RSV-A and RSV-B Neutralizing Abs | Up to End of Study (Day 730) |
| Part B: SRR of Serum RSV-A and RSV-B Neutralizing Abs at Postbaseline/Baseline Levels | Baseline up to Day 730 |
| Part B: Number of Participants with ≥2-Fold Increase in RSV-A and RSV-B Neutralizing Abs | Up to End of Study (Day 730) |
| Part B: GMC of Serum RSV Pre-F Binding Abs | Up to End of Study (Day 730) |
| Part B: GMFR of Serum RSV Pre-F Binding Abs | Up to End of Study (Day 730) |
| Part B: SRR of Serum RSV Pre-F Binding Abs at Postbaseline/Baseline Levels | Baseline up to End of Study (Day 730) |
| Part B: Number of Participants with ≥2-Fold Increase in RSV Pre-F Binding Abs | Up to End of Study (Day 730) |
| Part B: GMT of Serum RSV-A and RSV-B Neutralizing Abs | Up to End of Study (Day 730) |
| Part A: Geometric Mean Concentration (GMC) of Serum RSV Prefusion Conformation of the F Protein (Pre-F) Binding Abs | Up to End of Study (Day 730) |
| Part A: Geometric Mean Fold-Rise (GMFR) of Serum RSV Pre-F Binding Abs | Up to End of Study (Day 730) |
| Part A: SRR of Serum RSV Pre-F Binding Abs at Postbaseline/Baseline Levels | Baseline up to Day 730 |
| Part A: Number of Participants with ≥2-Fold Increase in RSV Pre-F Binding Abs | Up to End of Study (Day 730) |
| Part A: GMT of Serum RSV-A and RSV-B Neutralizing Abs at Day 29 | Day 29 |
Countries
Canada, Puerto Rico, United Kingdom, United States
Outcome results
None listed